NewAmsterdam Pharma Company N.V. (NAMS)

NGM – Real Time Price. Currency in USD

27.64

+0.02 (0.07%)

Market open: Aug 12, 2026, 10:43 AM EDT

27.62

0.00 (0.00%)

Previous after-hours: Aug 11, 2026, 7:34 PM EDT

Summary
News
Chart
Financial
Dividends
Forecast
Ownership
Profile

Revenue

Gross Profit

Operating Income

Net Income

Income Statement
Balance Sheet
Cash Flow

Income Statement (Annual)

Financials in millions USD. Fiscal year is January – December.

Name

2025

2024

2023

2022

Total Revenue

23M

46M

14M

103M

Cost of goods sold

-220K

-113K

-49K

-9K

Gross Profit

22M

45M

14M

103M

Operating expenses (excl. COGS)

-248M

-222M

-195M

-104M

Operating Income

-226M

-176M

-181M

-1M

Non-operating income, total

22M

-65M

-21M

Pretax income

-204M

-242M

-177M

-23M

Equity in earnings

Taxes

-27K

Non-controlling/minority interest

After tax other income/expense

Net income before discontinued operations

-204M

-242M

-177M

-23M

Discontinued operations

Net income

-204M

-242M

-177M

-23M

Dilution adjustment

Preferred dividends

NewAmsterdam Pharma Company N.V. (NAMS)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

NewAmsterdam Pharma Company N.V. (NAMS)

Income Statement (Annual)

Income Statement (Annual)

Search stocks

NewAmsterdam Pharma Company N.V. (NAMS)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

NewAmsterdam Pharma Company N.V. (NAMS)

Income Statement (Annual)

Income Statement (Annual)